Public health activists estimate Roche earned significantly more from risdiplam, a spinal muscular atrophy drug, than its development costs. Roche disputes this, citing expenses from unsuccessful ...

Risdiplam is a potential rival to Biogen’s Spinraza (nusinersen), a spinally injected antisense drug that tells the body to produce the SMN protein that is defective in patients with SMA and has ...

While Roche’s oral risdiplam has been tipped by some analysts to be a big contender in the market for spinal muscular atrophy (SMA) treatments, Novartis’ research chief Jay Bradner has a ...

He had a hunch that the oral SMA treatment risdiplam, made by Roche, had prenatal potential because it’s safe for kids and ...

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

Natco revealed in a “legal update regarding Risdiplam launch in India” that the “company has decided to price the product (Risdiplam) at Rs 15,900” per 60 mg bottle. An individual with a ...